Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2010 Financial Results
Date:2/24/2011

ns for more information on ViroPharma and our business.

Disclosure NoticeCertain statements in this press release contain forward-looking statements that involve a number of risks and uncertainties. Forward-looking statements provide our current expectations or forecasts of future events. Forward looking statements in this press release include our financial guidance for 2011, our ability to continue to successfully commercialize Cinryze, our ability to complete manufacturing scale up procedures, and receive regulatory approvals in the time frames anticipated, our ability to manufacture specified quantities of Cinryze utilizing the existing manufacturing process or additional manufacturing procedures; our ability to develop life cycle management plans for Cinryze, including designing and commencing clinical studies for additional indications, and pursuing regulatory approvals in additional territories; and our ability to conduct additional studies in the timeframes we anticipate and generate positive results with a Cinryze subcutaneous formulation, Cinryze for antibody mediated rejection and delayed graft function, as well as VP20621 for recurrence of C. difficile.

Our actual results may vary depending on a variety of factors, including:

  • the development of competitive generic versions of oral Vancocin;
  • our ability to receive regulatory approval for the use of Cinryze for additional indications and formulations and in additional territories including the EU in the timeframes we anticipate or at all;
  • manufacturing, supply or distribution interruptions, including but not limited to our ability to acquire adequate supplies of Vancocin and Cinryze to meet demand for each product;
  • our ability to increase manufacturing capacity for Cinryze and the timing and results thereof;
  • our ability to receive necessary regulatory approvals related to manufacturing capacity increases for Cinryze;
  • the
    '/>"/>

  • SOURCE ViroPharma Incorporated
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related biology technology :

    1. ViroPharma to Present at Three September Healthcare Conferences
    2. ViroPharma to Present at Three October Healthcare Conferences
    3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
    4. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
    5. ViroPharma to Present at Three November Healthcare Conferences
    6. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
    7. ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes
    8. ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009
    9. ViroPharma Incorporated Reports First Quarter 2009 Financial Results
    10. ViroPharma Incorporated Honored by the National Organization for Rare Disorders
    11. ViroPharma to Present at Two June Healthcare Conferences
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/10/2014)... D.C., April 15, 2014 -- According to the ... to nuclear security comes from terrorists acquiring sufficient ... to construct a crude nuclear explosive device. The ... nuclear trafficking have involved gram-level quantities, which can ... , According to a new study appearing this ...
    (Date:7/10/2014)... fractional quantum Hall effect in bilayer graphene and shown ... by an electric field. , The fractional quantum ... thin sheets are exposed to large magnetic fields, is ... individual electrons behave as a single system. However, while ... many details of this collective behavior remain not well ...
    (Date:7/10/2014)... will see the two universities and NPL collaborate to ... and industry and their complementary academic strengths., Working with ... shape the scientific priorities of the UK. The establishment ... 300 high-calibre PhD students, will provide a pipeline of ... potential of the Laboratory will be grown through the ...
    (Date:1/15/2014)... 15, 2014   Niagara Thermal Products is proud ... BioBlower Technologies LLC ("B3") as the critical thermal component ... from the Army Corps of Engineers.  B3 has developed ... biological contaminants and destroys VOCs and other chemical pollutants, ...
    Breaking Biology Technology:Sensitive detection method may help impede illicit nuclear trafficking 2Columbia researchers observe tunable quantum behavior in bilayer graphene 2Columbia researchers observe tunable quantum behavior in bilayer graphene 3Universities of Surrey and Strathclyde selected as strategic partners in the future operation of the National Physical Laboratory 2Universities of Surrey and Strathclyde selected as strategic partners in the future operation of the National Physical Laboratory 3Niagara Thermal Products LLC Selected as Critical Supplier for Buffalo BioBlower Air Purification Systems 2
    ... QUEBEC CITY, Oct. 23 /PRNewswire-FirstCall/ - AEterna Zentaris ... "Company") a global biopharmaceutical company focused on endocrine ... completed its previously announced registered direct offering of ... and common share purchase warrants to certain institutional ...
    ... A team of engineers from the University of ... and circuits, demonstrating a novel, self-assembling method for ... to grow or obtain otherwise. The research ... into a variety of useful, nanoscale materials including ...
    ... Tolerx, Inc., a biopharmaceutical company developing novel therapies intended ... specifically modulating T-cell activity, today presented dose optimization data ... subjects with type 1 diabetes. Otelixizumab is a targeted ... 3 clinical study in subjects with new-onset autoimmune type ...
    Cached Biology Technology:AEterna Zentaris Receives US$5.5 Million from Institutional Investors 2AEterna Zentaris Receives US$5.5 Million from Institutional Investors 3Penn study: Transforming nanowires into nano-tools using cation exchange reactions 2Penn study: Transforming nanowires into nano-tools using cation exchange reactions 3Tolerx Presents Otelixizumab Phase 2 Dose Optimization Data At The IDF's 20th World Diabetes Congress 2Tolerx Presents Otelixizumab Phase 2 Dose Optimization Data At The IDF's 20th World Diabetes Congress 3
    (Date:7/10/2014)... in your popcorn or soap might not be ape friendly, ... to an analysis in the Cell Press journal Current ... vegetable oil has already led to the conversion of Southeast ... in particular. If guidelines are not put in place very ... from Asia into Africa will be bad news for great ...
    (Date:7/10/2014)... Marshall Institute for Interdisciplinary Research (MIIR) and the ... today announced they will be partnering with an ... , Under the agreement with Shanghai-based HD Biosciences ... costs and risks of discovery and development of ... any intellectual property and commercialization rights to products ...
    (Date:7/10/2014)... Amidst the astounding complexity of the billions of ... brain, how do nerve cells decide how far to ... they coordinate these events within the developing brain? , ... of The Scripps Research Institute (TSRI) have shed new ... protein plays a far more sophisticated role in neuron ...
    Breaking Biology News(10 mins):Hunger for vegetable oil means trouble for Africa's great apes 2Marshall University to partner with international company in drug development venture 2Scripps Florida scientists shed new light on nerve cell growth 2
    ... researchers have identified the neurocircuit that controls the brain's ... be possible to understand psychiatric disorders, such as anxiety ... brain. , They accomplished this using an adapted version ... that enables analysis of function in the brain. , ...
    ... the January/February 2007 issue of Physiological and Biochemical Zoology, ... may respond to water diversion and climate change. Endangered ... spawn, and a lake in Western China, where they ... and becoming increasingly more saline--leading to surprising adjustments to ...
    ... blood oxygen levels of a baby during labor--expected to ... benefit, report researchers in a National Institutes of Health ... saturation monitoring, was designed for use along with electronic ... measure changes in fetal oxygen levels. Designers of ...
    Cached Biology News:Emotional control circuit of brain's fear response discovered 2Emotional control circuit of brain's fear response discovered 3Climate change has surprising effect on endangered naked carp 2Technology for monitoring fetal oxygen during labor offers no apparent benefit 2Technology for monitoring fetal oxygen during labor offers no apparent benefit 3
    KRIT1 Immunogen: KRIT1 (NP_004903, 637 a.a. ~ 737 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
    Evolutionarily conserved signaling intermediate in Toll pathway...
    Anti-MMP-25 (Membrane-type MMP-6, Mt6MMP), hinge region; rabbit host...
    Sheep polyclonal to Streptomycin ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule: Streptomycin conjugated to BSA....
    Biology Products: